References in periodicals archive ?
Multiple roles for the receptor tyrosine kinase axl in tumor formation.
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
Muller-Tidow et al have analyzed expression of all human receptor tyrosine kinases (n=56) in malignant tumors of different origins and normal control samples by quantitative real-time RT-PCR.
Schlessinger, together with other scientists from the laboratories and Kolltan, co-authored an article in the Proceedings of the National Academy of Sciences (PNAS), titled "Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region".
M2 PHARMA-July 30, 2013-Kolltan licenses antibody targeting Her3 receptor tyrosine kinase from MedImmune(C)2013 M2 COMMUNICATIONS
ARQ 197 is a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, while erlotinib is an inhibitor of epidermal growth factor receptor.
reached a collaboration and licensing agreement for Volitinib (HMPL-504), a new targeted therapy and an inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer.
FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis and tumor cell survival.
The topics include ligand-based drug design, drug-like properties and decision making in medicinal chemistry, in vivo imaging in drug discovery, peptide and protein drug design, enzyme inhibitors: biostructure-based and mechanism-based design, ion channels: structure and function, acetylcholine, dopamine and serotonin, opioid and cannabinoid receptors, targeting receptor tyrosine kinases, and antibiotics.
These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumour angiogenesis, and maintenance of the tumour microenvironment.
The themes are historical perspectives, principles of cellular signaling by receptor tyrosine kinases (RTKs), specific molecular features and mechanisms of key RTK families, development, and disease and medicine.
Thus, biochanin A may be an effective chemotherapeutic agent for breast cancer because of its ability to affect both hormonal receptors and receptor tyrosine kinases and to decrease intracellular ROS levels.

Full browser ?